Original Data

The Effect of PPARγ-Agonism on LDL Subclass Profile in Patients with Type 2 Diabetes and Coronary Artery Disease

Riikka Lautamäki¹, Pirjo Nuutila^1,2, K.E. Juhani Airaksinen², Aila Leino³, Heikki Hiekkanen⁴, Marian Turiceanu¹, Murray Stewart⁵, Juhani Knuuti¹, Tapani Rönnemaa²

Keywords: type 2 diabetes, coronary artery disease, PPAR-agonism, lipoproteins

Abstract

Patients with type 2 diabetes (T2DM) often present a preponderance of small, dense LDL particles (small-LDL), which are associated with a high risk of myocardial infarction. Some studies suggest that PPARγ-agonists increase LDL cholesterol but have divergent effects on various LDL subclasses in T2DM patients. We studied the effect of rosiglitazone on the LDL subclass profile in T2DM patients with verified coronary artery disease (CAD). 58 patients with T2DM (HbA1c < 8.5%) and CAD were enrolled in a 16-week, randomized, double-blind and placebo-controlled trial with rosiglitazone 8mg/day (n = 29) or placebo (n = 29). The LDL subclass profile was measured with gel electrophoresis. Rosiglitazone improved insulin sensitivity and glycemic control. Total cholesterol did not change after rosiglitazone treatment (p = 0.062, ANCOVA adjusted for gender and baseline values), whereas LDL (including IDL) cholesterol increased from 2.33 ± 0.48 to 2.67 ± 0.61 mmol/l (p = 0.002 vs. baseline, p = 0.0497 vs. placebo) and large buoyant LDL (large-LDL > 250Å) increased from 1.31 ± 0.36 to 1.46 ± 0.42 mmol/l (p = 0.010 vs. baseline, p = 0.044 vs. placebo) in the rosiglitazone group. No significant changes occurred to the concentration of small-LDL (< 250Å), the average LDL particle size, or HDL or triglyceride concentrations. Whole-body insulin sensitivity was associated with the average LDL particle size after intervention in the whole population (r = 0.40, p = 0.002) and in the rosiglitazone group (r = 0.43, p = 0.020). In conclusion, in T2DM patients with CAD, rosiglitazone treatment significantly increases the concentration of large (buoyant) LDL cholesterol, but not of small dense LDL cholesterol. The long term consequences of this divergent effect of rosiglitazone on LDL subfractions require further exploration.

Fulltext: HTML , PDF (286KB)

This article has been cited by other articles:

	Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type-2 diabetes Rizzo M, Vekic J, Koulouris S, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS Angiology 2010. 61(6):584-590
	Cardiovascular risk of rosiglitazone: another perspective Waksman JC J Pharm Pharmacol 2008. 60(12):1573-1582
	Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus Borra R, Lautamäki R, Parkkola R, Komu M, Sijens PE, Hällsten K, Bergman J, Iozzo P, Nuutila P Metabolism 2008. 57(10):1445-1451
	The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Rizzo M, Christ ER, Rini GB, Spinas GA, Berneis K Expert Opin Pharmacother 2008. 9(13):2295-2303
	Clinical trials with thiazolidinediones in subjects with Type 2 diabetes - is pioglitazone any different from rosiglitazone? Doggrell SA Expert Opin Pharmacother 2008. 9(3):405-420
	Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, Christ ER Expert Opin Pharmacother 2008. 9(3):343-349
	The Atherogenic Dyslipidemia of Metabolic Syndrome - Are there New Effective Therapeutic Options Beyond Statins? Anfossi G, Trovati M Curr Drug Ther 2007. 2(3):177-195
	The 'Forgotten' Bile Acid Sequestrants: Is Now a Good Time to Remember? Bays H, Goldberg R Am J Ther 2007. 14(6):567-580